Uncategorized
Editas Medicine and Bristol Myers Squibb Expand T Cell Therapy Collaboration; KalVista Pharmaceuticals Seeks Partnership for Preclinical Hereditary Angioedema Program
Editas Medicine, Bristol Myers Squibb, T cell therapy, collaboration, KalVista Pharmaceuticals, preclinical program, hereditary angioedema (HAE), partnership.
Federal Trade Commission Challenges Novo Nordisk’s Ozempic and Over 300 ‘Junk’ Patent Listings in FDA Database
FTC, Novo Nordisk, Ozempic, FDA, patent listings, crackdown, junk patents, pharmaceutical industry, intellectual property, drug development.
Lilly’s Future Brightens with Increased Visibility on Mounjaro and Zepbound Production Capacity
Lilly, Mounjaro, Zepbound, production capacity, financial outlook, pharmaceutical industry, drug manufacturing.
Harmony Pharmaceuticals Expands into Rare Genetic Epilepsies with Acquisition of Epygenix Therapeutics
Harmony Pharmaceuticals, Epygenix Therapeutics, rare genetic epilepsies, acquisition, treatment, research, development, collaboration, genetic mutations, Dravet syndrome, CDK-like kinase inhibitors
Enlaza Secures $100M for Groundbreaking Irreversible Protein Binding Technology
Enlaza, funding, investment, protein binding, irreversible, biotechnology, medical research, drug development, therapeutics.
Novartis Invests $180M in PeptiDream to Boost Radiopharmaceutical Development
Novartis, PeptiDream, radiopharmaceuticals, investment, drug development, partnership, targeted therapies, cancer treatment, radioactive isotopes.
Prime Medicine Secures FDA Approval for Pioneering Gene Editing Therapy Trial
Prime Medicine, FDA approval, gene editing, clinical trial, innovative therapy, genetic diseases
FDA Approval Milestones: X4 Pharmaceuticals, Pfizer, and Genmab Secure Nods for Rare Disease and Cervical Cancer Treatments
FDA, X4 Pharmaceuticals, Pfizer, Genmab, rare disease, cervical cancer, drug approval, treatment, healthcare, biotechnology.
X4 Pharmaceuticals’ Xolremdi Granted Approval for Treating Rare Immunodeficiency Disorder
X4 Pharmaceuticals, Xolremdi, approval, rare immunodeficiency disorder, WHIM syndrome, FDA, treatment, breakthrough therapy, CXCR4 antagonist.
Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion
Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.